Updating on my last note, in this post I will look at Illumina and Grail's prospects for growth in 2025, and beyond. One of the reasons I have suggested in past notes why Illumina was so keen to ...

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through ...

Evercore ISI analyst Vijay Kumar lowered the firm’s price target on Illumina (ILMN) to $180 from $184 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech ...

Illumina, Inc. (NASDAQ:ILMN) was removed from the index. Year to date, the stock has increased around 8%, underperforming iShares Core S&P Mid-Cap ETF (NYSE:IJH). The provider of DNA sequencing ...

Illumina is an applied genomics technology company that was founded in 1998 with the mission statement: ‘To improve human health by unlocking the power of the genome’. Over the past two ...

Baron Global Advantage Fund highlighted stocks like Illumina, Inc. (NASDAQ:ILMN) in the third quarter 2024 investor letter.

BusinessWire India Bengaluru (Karnataka) [India], December 6: Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today celebrated the opening of a global ...